<DOC>
	<DOCNO>NCT00181948</DOCNO>
	<brief_summary>This 6-week , unblinded study use medication Strattera child adolescent attention deficit hyperactivity disorder ( ADHD ) fail respond adequate trial stimulant treatment . Specific hypotheses follow : Hypothesis 1 : ADHD symptomatology youth ADHD responsive Strattera treatment short term . Hypothesis 2 : Strattera treatment ( dose 120 mg/day 1.2 mg/kg/day ) child adolescent ADHD safe well tolerate .</brief_summary>
	<brief_title>Strattera Treatment Children With ADHD Who Have Poor Response Stimulant Therapy</brief_title>
	<detailed_description>Strattera ( atomoxetine ) non-stimulant presynaptic norepinephrine reuptake inhibitor recently approve Food Drug Administration use child , adolescent adult patient ADHD . Atomoxetine potent inhibitor presynaptic norepinephrine transporter minimal affinity noradrenergic receptor neurotransmitter transporter receptor . Thus , Strattera could viable alternative treatment ADHD individual respond stimulant . The purpose study ass effectiveness , safety tolerability Strattera youth , age 6-17 year ADHD fail respond adequate trial stimulant treatment . If initial study show proof concept , follow-up study randomize clinical trial .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<criteria>Male female outpatient 617 year age . Subjects diagnosis attention deficit hyperactivity disorder ( ADHD ) , Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) , manifest clinical evaluation confirm structured interview . ADHD rating scalesymptom checklist &gt; 24 Subjects past history depression , bipolar disorder , anxiety disorder ( include obsessive compulsive disorder [ OCD ] ) without current disorder &gt; 3 month ascertain structured diagnostic interview clinical exam . Subjects treat anxiety disorder depression ( nonMAOI antidepressant [ e.g. , SSRIs , bupropion , venlafaxine ] benzodiazepine ) stable medication regimen least three month , disorder specific Clinical Global Impression ( CGI ) severity score â‰¤ 3 ( mildly ill ) score HamiltonDepression HamiltonAnxiety Rating Scale 15 ( mild range ) include study . Subjects past present history tic eligible . Subjects past history substance use disorder drug alcohol free &gt; 6 month . Subjects mild case asthma allergy include . Potential subject fail adequate trial stimulant define : Subjects intolerable side effect stimulant , Poor response ( ADHD CGII &gt; 3 ) least 4 week &gt; 1.0 mg/kg/day methylphenidate product ; &gt; 0.5 mg/kg/day amphetamine product . Only Englishspeaking subject allow study follow reason : 1. assessment instrument available adequately standardized language ; 2. clinical trial facility locate Cambridge Massachusetts General Hospital ( MGH ) main campus without availability translator ; 3. psychiatric questionnaire evaluation tax add complexity translator potential make patient experience even exhaust . Any clinically unstable psychiatric condition include follow : acute psychosis , acute panic , acute OCD , acute mania , acute suicidality , acute substance use disorder ( alcohol drug ) , sociopathy , criminality . Any metabolic , neurological , hepatic , renal , cardiovascular , hematological , ophthalmic , endocrine disease . Clinically significant abnormal baseline laboratory value include follow : Values deviate great 20 % normal range laboratory standard basic metabolic screen complete blood count . Exclusionary blood pressure parameter include value 140 ( systolic ) 90 ( diastolic ) . Exclusionary electrocardiogram ( ECG ) parameter include QTC &gt; 460 msec , QRS &gt; 120 msec , PR &gt; 200 msec . Subjects ECG evidence ischemia arrhythmia review independent cardiologist . Mental retardation ( intelligence quotient [ I.Q . ] &lt; 75 ) . Organic brain disorder . Seizures . Pregnant nursing female . Subjects current adequate treatment ADHD history previous adequate trial Strattera . Prior hypersensitivity atomoxetine . MAOI antidepressant use currently within two week start study . Urinary retention bladder dysfunction . Narrow angle glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>ADHD</keyword>
	<keyword>child</keyword>
	<keyword>stimulant non-responders</keyword>
	<keyword>Strattera</keyword>
</DOC>